New oral drugs in older patients: A review of idarubicin in elderly patients

Diana Crivellari; Davide Lombardi; Simon Spazzapan; Andrea Veronesi; Giuseppe Toffoli

doi:10.1016/S1040-8428(03)00120-3

New oral drugs in older patients: A review of idarubicin in elderly patients

Diana Crivellari, Davide Lombardi, Simon Spazzapan, Andrea Veronesi, Giuseppe Toffoli

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.

Original language	English
Pages (from-to)	153-163
Number of pages	11
Journal	Critical Reviews in Oncology/Hematology
Volume	49
Issue number	2
DOIs	https://doi.org/10.1016/S1040-8428(03)00120-3
Publication status	Published - Feb 2004

Keywords

Elderly breast cancer patients
Oral anthracyclines
Oral idarubicin

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/S1040-8428(03)00120-3

Fingerprint Dive into the research topics of 'New oral drugs in older patients: A review of idarubicin in elderly patients'. Together they form a unique fingerprint.

Cite this

@article{d18f75cc06914823b8a4ded40561f8a5,

title = "New oral drugs in older patients: A review of idarubicin in elderly patients",

abstract = "Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.",

keywords = "Elderly breast cancer patients, Oral anthracyclines, Oral idarubicin",

author = "Diana Crivellari and Davide Lombardi and Simon Spazzapan and Andrea Veronesi and Giuseppe Toffoli",

year = "2004",

month = feb,

doi = "10.1016/S1040-8428(03)00120-3",

language = "English",

volume = "49",

pages = "153--163",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - New oral drugs in older patients

T2 - A review of idarubicin in elderly patients

AU - Crivellari, Diana

AU - Lombardi, Davide

AU - Spazzapan, Simon

AU - Veronesi, Andrea

AU - Toffoli, Giuseppe

PY - 2004/2

Y1 - 2004/2

N2 - Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.

AB - Idarubicin (IDA) is a structural analogue of daunorubicin with the same mechanism of action. Unlike the other currently available anthracyclines, it has a significant oral bioavailability, which makes it particularly attractive for the treatment of elderly patients. IDA resulted at least as effective as daunorubicin for acute nonlymphocytic leukemia and additional data are in analysis as far as lymphomas and breast cancer are concerned. Adverse effects are mainly hematological, while hair loss, mucositis and cardiotoxicity are less frequently reported with IDA than with other anthracyclines. The pharmacokinetics, activity, adverse effects and new modalities of oral administration are reviewed.

KW - Elderly breast cancer patients

KW - Oral anthracyclines

KW - Oral idarubicin

UR - http://www.scopus.com/inward/record.url?scp=0842285393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842285393&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(03)00120-3

DO - 10.1016/S1040-8428(03)00120-3

M3 - Article

C2 - 15012975

AN - SCOPUS:0842285393

VL - 49

SP - 153

EP - 163

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -